Lantheus, Point Biopharma announces FDA grants FTD for 177Lu-PNT2002

Lantheus (LNTH) and POINT Biopharma Global (PNT) announced the U.S. Food and Drug Administration, FDA, has granted Fast Track designation, FTD, for 177Lu-PNT2002 for the treatment of metastatic castration resistant prostate cancer. "Fast track designation by the FDA is an important milestone and recognizes the potential for 177Lu-PNT2002 to address the significant unmet need for mCRPC patients," said Jean-Claude Provost, M.D., Chief Medical Officer at Lantheus. "We are encouraged by the FDA’s decision as it reflects the need for FDA approved and widely available treatments for these patients. This designation will allow us to work closely with the FDA, along with our partner POINT, to quickly advance 177Lu-PNT2002, with the potential to make a meaningful difference for patients who require new treatment options."